Zmapp: Phase I/II started

NIH’s National Institute of Allergy and Infectious Diseases (NIAID) began an open-label, U.S. and Liberian Phase I/II trial to compare IV ZMapp every 3 days for 3 doses vs. standard of care (SOC). NIAID said if the trial does not find a “significant difference” in the ZMapp vs. SOC portion, it may go on to enroll additional patients to evaluate other experimental Ebola therapies. SOC includes providing IV fluids, balancing electrolytes, maintaining oxygen status and blood pressure and treating other infections. ...